Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
SAN DIEGO, March 07, 2016 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that it has issued inducement awards to two new non-executive employees.
TRACON issued inducement awards to two new non-executive officer employees on March 3, 2016. The inducement awards consist of options to purchase an aggregate of 11,600 of the Company's common stock and were granted in accordance with NASDAQ Listing Rule 5635(c)(4) under the Tracon Pharmaceuticals, Inc. 2015 Equity Incentive Plan (the "2015 Plan”). Each option has an exercise price per share equal to $6.36, which was the closing price of one TRACON share on the Nasdaq Global Market on the date of grant. The options vest over four years, with 25% of the option shares vesting on the first anniversary of the date of grant and the remaining 75% of the option shares vesting in monthly installments over the three years thereafter. The options have a ten-year term, and are subject to the terms and conditions of the 2015 Plan and applicable stock option agreement.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The company’s clinical-stage pipeline includes two product candidates: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers and wet AMD through a collaboration with Santen Pharmaceutical Company Ltd., and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Casey Logan Chief Business Officer (858) 550‐0780 ext. 236 [email protected] Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 [email protected]
